Multiplexed discrimination of SARS-CoV-2 variants via plasmonic-enhanced fluorescence in a portable and automated device.

Multiplexed discrimination of SARS-CoV-2 variants via plasmonic-enhanced fluorescence in a portable and automated device.

Publication date: Sep 21, 2023

Portable assays for the rapid identification of lineages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to aid large-scale efforts in monitoring the evolution of the virus. Here we report a multiplexed assay in a microarray format for the detection, via isothermal amplification and plasmonic-gold-enhanced near-infrared fluorescence, of variants of SARS-CoV-2. The assay, which has single-nucleotide specificity for variant discrimination, single-RNA-copy sensitivity and does not require RNA extraction, discriminated 12 lineages of SARS-CoV-2 (in three mutational hotspots of the Spike protein) and detected the virus in nasopharyngeal swabs from 1,034 individuals at 98. 8% sensitivity and 100% specificity, with 97. 6% concordance with genome sequencing in variant discrimination. We also report a compact, portable and fully automated device integrating the entire swab-to-result workflow and amenable to the point-of-care detection of SARS-CoV-2 variants. Portable, rapid, accurate and multiplexed assays for the detection of SARS-CoV-2 variants and lineages may facilitate variant-surveillance efforts.

Concepts Keywords
Biomed Assays
Coronavirus Automated
Fluorescence Cov
Workflow Detection
Device
Discrimination
Enhanced
Fluorescence
Lineages
Multiplexed
Plasmonic
Portable
Sars
Variant
Variants

Semantics

Type Source Name
disease VO device
disease VO Severe acute respiratory syndrome coronavirus 2
disease VO report
disease IDO assay
drug DRUGBANK Gold

Original Article

(Visited 1 times, 1 visits today)